IP Library › Granted Patent US 10,583,149
Granted Patent B2
US 10,583,149 · App. 15/625,945 · Granted Mar 10, 2020

MiRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway

Inventors: Eugene Berezikov (Haren, NL); Jos Bernard Poell (Utrecht, NL); Willemijn Maria Gommans (Voorschoten, NL); Rick Jan van Haastert (Amersfoort, NL); Andreas Alphons F. L. van Puijenbroek (Boxtel, NL); Roeland Quirinus Jozef Schaapveld (Bussum, NL); Gregoire Pierre Andre Prevost (Antony, FR)
Assignees: INTERA TECHNOLOGIES B.V.; KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN
A61K31/7088C12N15/111C12N15/113C12N15/1135C12Q1/6809C12N2310/113C12N2310/141C12N2320/10C12N2320/31C12N2330/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,149
App. No.
15/625,945
Granted
Mar 10, 2020
Kind
B2
Abstract

The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.

Claims (34)

1. A method for inhibiting growth and/or reducing viability of melanoma cells, the method comprising: administering to said cells an effective amount of at least one miRNA molecule or a composition comprising an effective amount of said at least one miRNA molecule, wherein said at least one miRNA molecule is selected from the group consisting of:

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:160 and 161 and having at least 70% identity with SEQ ID NO:99 or 100 (miRNA-10b),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:162 and 163 and having at least 70% identity with SEQ ID NO:101 or 102 (miRNA-18b),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:166 and having at least 70% identity with SEQ ID NO:105 (miRNA-128),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:170 and having at least 70% identity with SEQ ID NO:109 (miRNA-184),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:171 and having at least 70% identity with SEQ ID NO:110 (miRNA-190b),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:173 and having at least 70% identity with SEQ ID NO:112 (miRNA-3157),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in a seed sequence selected from the group consisting of SEQ ID NOs:157, 158 and 159 and having at least 70% identity with SEQ ID NO:96, 97 or 98 (miRNA-7) and/or

a precursor of said miRNA molecule.

2. The method of claim 1 , wherein said composition further comprises an miRNA molecule, isomiR, or precursor thereof, selected from the group consisting of:

a) at least one of miRNA-137, Let-7, and Let-7a, and/or an isomiR or a precursor thereof and/or,

b) at least one antagomir of miRNA-221 and/or miRNA-222, and/or a precursor thereof.

3. The method of claim 1 , wherein said at least one miRNA molecule is an miRNA-7 molecule or an isomiR thereof or a precursor thereof.

4. The method of claim 1 , wherein a precursor of said miRNA is administered.

5. The method of claim 1 , wherein an isomiR of said miRNA is administered.

6. The method of claim 1 , wherein the miRNA molecule is a modified miRNA molecule.

7. A method for inhibiting growth and/or reducing viability of melanoma cells, said method comprising: administering to said cells an effective amount of at least one miRNA molecule or a composition comprising an effective amount of said at least one miRNA molecule, wherein said at least one miRNA molecule is selected from the group consisting of:

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:190 and having at least 70% identity with SEQ ID NO:129 (miRNA-610),

an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:185 and having at least 70% identity with SEQ ID NO:124 (miRNA-95),

and/or

a precursor of said miRNA molecule.

8. The method according to claim 7 , wherein said composition further comprises an miRNA molecule, isomiR, or precursor thereof, selected from the group consisting of:

a) at least one of miRNA-137, Let-7, and Let-7a, and/or an isomiR or a precursor thereof and/or,

b) at least one antagomir of miRNA-221 and/or miRNA-222, and/or a precursor thereof.

9. The method according to claim 7 , wherein a precursor of said miRNA is administered.

10. The method according to claim 7 , wherein an isomiR of said miRNA is administered.

11. The method according to claim 7 , wherein the miRNA molecule is a modified miRNA molecule.

12. A method for inhibiting growth and/or reducing viability of melanoma cells, said method comprising: administering to said cells an effective amount of an miRNA molecule from 6 to 30 nucleotides comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO:188 and having at least 70% identity with SEQ ID NO: 127 (miRNA-193a) and/or a precursor of said miRNA molecule or a composition comprising an effective amount of said miRNA molecule and/or said precursor of said miRNA molecule.

13. The method according to claim 12 , wherein said composition further comprises an miRNA molecule, isomiR, or precursor thereof, selected from the group consisting of:

a) at least one of miRNA-137, Let-7, and Let-7a, and/or an isomiR or a precursor thereof and/or,

b) at least one antagomir of miRNA-221 and/or miRNA-222, and/or a precursor thereof.

14. The method according to claim 12 , wherein a precursor of said miRNA is administered.

15. The method according to claim 12 , wherein an isomiR of said miRNA is administered.

16. The method according to claim 12 , wherein the miRNA molecule is a modified miRNA molecule.

Priority Claims (1)
EP 10168592 · Jul 6, 2010 · regional
Continuity (4)
Continuation 13734414 · Jan 4, 2013
Continuation PCTNL2011050476 · Jul 1, 2011
Provisional Application 61361787 · Jul 6, 2010
Related Publication 20170304348A1 · Oct 26, 2017